STF-083010对肾脏缺血-再灌注损伤的保护作用

目的 观察STF083010对急性肾缺血-再灌注损伤的作用,探讨其损伤保护作用的机制.方法 选择健康雄性SD大鼠30只,随机分为假手术组(打开腹腔)、I-R组(建立大鼠肾I-R损伤模型)与STF083010组.分别在缺血-再灌注24h后处死大鼠,取血液和肾组织.全自动生化仪检测各组血清尿素氮(BUN)及肌酐(Scr)水平.PAS染色观察大鼠肾组织病理变化,免疫组化检测肾脏组织中XBP1、GRP78蛋白的表达.Quantitative real-time PCR(QPCR)测定大鼠肾组织标本中XBP1、GRP78 mRNA水平.结果 I-R组肌酐、尿素氮水平与假手术组相比差异均有统计学意义(P＜0.05).STF-083010组与I-R组相比,差异亦有统计学意义(P＜0.05).PAS病理图片可见STF-083010组肾小管损伤较I-R组明显减轻(P＜0.05);免疫组化检测显示STF-083010组XBP1的表达较I-R组明显降低(P＜0.05),STF-083010组GRP78蛋白的表达较I/R组明显升高;QPCR结果显示STF-083010组XBP1 mRNA水平较I-R组明显降低(P＜0.05),STF-083010组GRP78 mRNA较I-R组明显升高(P＜0.05).结论 STF-083010可以对大鼠肾脏缺血-再灌注损伤性保护作用.     

乙型肝炎病毒特异性转移因子的研究

制备一种乙型肝炎病毒特异性转移因子制剂(HBV-STF),为临床应用提供有价值的实验依据.从人HBsAg阳性胎盘中制备了HBV-STF,并对其理化性质、免疫学活性进行了检测和初步的临床试用.每批样品经无菌试验、热原质检查、动物安全性试验等均符合药典要求.本品最大紫外吸收光谱在256±2 nm处,E260nm/E280nm比值大于2.7.其水解氨基酸含17种.对人T淋巴细胞E受体的激活试验结果显示,HBV-STF的Ea-RFc平均增高率在83.47%～103.48%之间,抗原特异性皮肤试验表明HBV-STF能刺激小鼠体内T淋巴细胞增殖,诱导小鼠跖趾部皮肤的迟发性变态反应.对HBV-STF的初步临床试用也取得明显效果,显示HBV-STF是一种可用于治疗乙肝的安全、有效的免疫调节剂.     

贺普丁联合抗乙肝特异性转移因子治疗慢性乙肝临床研究

目的　探讨贺普丁联合抗乙肝特异性转移因子治疗慢性乙型肝炎的临床疗效及安全性。方法　对照组常规保肝治疗的基础上 ,贺普丁 10 0 mg,每日 1次 ,连用 1年。治疗组在对照组的基础上加用抗乙肝特异性转移因子注射剂 2 mg,肌注 ,每日 1次 ,连用 3个月 ,停 3个月后继续用 3个月。治疗后 3、6、12个月时查血清肝功能、HBe Ag、HBVDNA和 CD4+ / CD8+ 。结果　对照组 /治疗组 HBe Ag阴转率 10 .5 2 %～ 42 .11% / 2 7.18%～ 6 6 .6 7% ;HBVDNA阴转率84.2 1%～ 73.6 8% / 86 .11%～ 94.44 % ;AL T复常率 6 5 .79%～ 71.0 5 % / 77.78%～ 88.89% ;CD4+ / CD8+ 1.17± 0 .10 /1.45± 0 .2 9。各项指标随时间推移明显改善。结论　贺普丁对 HBV有明显的抑制作用 ,联合抗乙肝特异性转移因子治疗 ,特异性提高机体免疫功能 ,能明显提高疗效、费用适宜 ,安全有效     

卵巢癌特异性转移因子的制备与鉴定

目的：为了卵巢癌手术后免疫治疗的需要,我们用透析法从用癌组织免疫的山羊脾及淋巴结制备了卵巢癌特异性转移因子（ＳＴＦ）。方法：按中国药典及白细胞粘附抑制试验（ＭＴＴ法）对ＳＴＦ的理化性质和免疫学性质进行了检测和鉴定。结果：所制备的卵巢癌ＳＴＦ符合转移因子质量具有对卵巢癌细胞抗原的特异性。在１５例卵巢癌病人的临床应用中,未发现任何毒副反应。结论：用该法制备的卵巢癌ＳＴＰ,可以安全地应用于卵巢的癌的免疫     

卵巢癌特异性转移因子的临床疗效研究

目的：探讨卵巢癌特异性转移因子（STF）治疗卵巢癌的临床疗效。方法：将121例卵巢癌患者随机分成实验组和对照组，两组分别为52例和69例。对照组给予手术、化疗等常规治疗，实验组则在常规治疗的同时加用卵巢癌STF。结果；实验组的生存率高于对照组，但差异尚无统计学意义（P〉0．05）．其中使用≥2疗程卵巢癌STF组的生存时间明显高于使用1个疗程组及对照组（P〈O．05），而使用1个疗程组与对照组比较差异无统计学意义（P〉0．05）。结论；卵巢癌STF对提高卵巢癌患者的生存率、延长其生存时间可能有效，且其疗效具有量-效关系。     

Maturation and current status of neuroscience: Data from the 1976 inventory of U.S. neuroscientists

The growth of neurosciences as a correlated field of brain and behavior was demonstrated by the increase since 1968 of publications, membership in the Society for Neuroscience, and attendance at its annual meetings. The extent and characteristics of the resultant pool of neuroscientists in 1976 was assessed from responses to a questionnaire that provided demographic, sociologic, and field specialization data. Information on research projects and their dollar support was obtained from the Smithsonian Science Information Exchange. Indicators from these data were compared with those obtained from earlier surveys and with aggregated data in the biomedical sciences. Since 1968–69 the number of scientists with Ph.D.'s increased their proportion of the pool of neuroscience personnel and those with M.D.'s decreased. More than half were employed in medical school settings and only one-quarter were engaged in full-time research. The ratios of dollar support to number of projects funded in 1968 and 1976 varied widely among scientific disciplines, as did fields of training and later research specialization. The indicator variability found in the subfields of neuroscience underscores the urgency of continued monitoring and the fallacy of using aggregated data to identify needs for personnel in specific fields.     

Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of Acyclovir

Delivering drugs via the ocular route has always been a challenge for poorly soluble drugs. The various anatomical and physiological barriers in the eye cavity hinder the residence of drugs within the corneal and precorneal regions. In this study, the nanosystem that could sufficiently deliver the poorly soluble Acyclovir topically via ocular route. Our nanosystem is composed of the biocompatible PLGA polymer stabilized with TPGS which possess a high emulsifying capacity and is also known as P-gp inhibitor. The optimized nanoparticles were prepared with 0.3% TPGS and had particle-size of 262.3?nm, zeta-potential of +15.14?mV. The physicochemical-characterization, ex vivo transcorneal permeation, ocular-irritation and Acyclovir ocular-availability, following topical ocular application of PLGA-NPs in rabbit eyes, were performed. The tested parameters and irritation by Draize’s test suggested the suitability and safety of PLGA-NPs for ocular use. An ultrahigh performance liquid chromatographic method was developed, validated, and applied to quantify Acyclovir in aqueous humor which was shown to be significantly higher (p?<?0.05) using the developed nanoparticles as compared to Acyclovir-aqueous suspension following their single topical ocular administration. Noticeable 2.78-, 1.71- and 2.2-times increased values of AUC_0–24h, t_1/2 (h) and MRT_0–24h were found, respectively, with the PLGA-TPGS-NPs as compared to ACY-AqS. These results demonstrate the superiority of delivering Acyclovir using a nanosystem compared to conventional methods.     

STF卡评价多酶清洗剂使用时效和清洗效果研究

目的探讨多酶清洗剂处理有机物污染器械的最佳预浸泡时间、使用有效时间及其清洗效果。方法将STF清洗检测卡放在多酶清洗液中预浸泡,再与器械一同上机器清洗,对多酶清洗剂的起效时间、使用有效时间和使用中的污染程度进行评价。结果STF清洗检测卡在多酶清洗剂中预浸泡3、5、7min后上机清洗,合格率分别为70．O％、75．O％、85．O％;STF清洗检测卡在使用中1、2、3、4h的多酶清洗剂浸泡7min,合格率分别为80．0％、66．7％、45．7％、40．O％;STF清洗检测卡在有酶与无酶两组清洗液测试差异有显著意义（P〈0．05）。结论多酶清洗剂最佳使用方法是现用现配。以器械的污染程度和数量设置多酶清洗剂的预浸泡时间和使用时间,应通过验证清洗流程和器械清洁度,在保证手术器械清洗质量的前提下,科学合理使用多酶清洗剂,达到清洗效果同时节省清洗成本。